Neurocrine's experimental drug misses primary goal in schizophrenia trial
12/09/2024 21:28
Sept 12 (Reuters) - Neurocrine Biosciences NBIX.O said its experimental drug did not achieve the primary goal in a mid-stage trial aimed at improving cognitive function in patients with schizophrenia. (Reporting by Puyaan Singh;Editing by Mohammed Safi Shamsi) ((Puyaan.Singh@thomsonreuters.com;))
Recent news on Neurocrine Biosciences
See all newsBrief: Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating Nbi-'567 In Adults With Alzheimer's Disease
Nxera Pharma's Partner Neurocrine Biosciences Receives Ind Acceptance From FDA For Phase 2 Study Of Nbi-1117567 For Alzheimer's Cognition
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte
Prader-Willi groups cite deaths tied to Neurocrine's genetic disorder drug, shares fall